drugset / Trial / NCT04500665
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
Phase 2
Recruiting
20 enrolled
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2026-07-31
- Completion
- 2026-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Colchicine | Small molecule | 0.3 mg | — |